Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 1,301–1,400 of 1,448
TRANSPORT MECHANISM OF BASIC FIBROBLAST GROWTH FACTOR (bFGF) THROUGH THE BLOOD-BRAIN BARRIER
Deguchi, Y., Okutsu, H., Naito, T., Okura, T., Yamada, S., Yuge, T., Furukawa, A., Ohtsuki, S., Hosoya, K., Terasaki, T., et al. (2000) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.15.supplement_104
Self-citationFibrin Formation and Dissolution in the Progression of Amyloid-Beta Pathology in Alzheimer's Disease
Paul, J. (2009) · Digital Commons - RU (Rockefeller University) · doi:10.48496/m50g-qv97
Drug Delivery Strategies: BBB–Shuttles
Prades, R., Teixidò, M., & Giralt, E. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735292-00364
석한나 (2014) · YUHSpace (Yonsei University Medical Library)
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Self-citationStopa, E. G., Duncan, J., Silverberg, G. D., Johanson, C. E., & Donahue, J. E. (2005) · CRC Press eBooks · doi:10.1201/9781420023404.sec3 · Cited by 4
Banks, W. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00227-x
Dorey, E. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-6258
Antyborzec, I. (2016) · Dublin City University Open Access Institutional Repository (Dublin City University)
The Search for Biomarkers in Alzheimer's Disease
Meiliana, A., & Wijaya, A. (2010) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v2i1.107 · Cited by 3
Guest, P. N. (2016) · St Andrews Research Repository (St Andrews Research Repository) · Cited by 1
Identification of functional variants in the Alzheimer’s disease candidate gene ABCA7
Clement, N. S. (2017) · Nottingham ePrints (University of Nottingham)
Banks, W. A. (2008)
de dans la maladie d'Alzheimer
Sévalle, J. (2009)
Klein, E. (2017) · Open Archive Toulouse Archive Ouverte (University of Toulouse) · Cited by 1
Blood-Brain Barrier–Targeted Nanotechnological Advances
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00005-7 · Cited by 2
The Roles of Diffusion and Bulk Flow in Neural Function and Alzheimer's Disease
Dauberman, W. N. (2017)
Paik, S. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0371596
Developing a Modern Mythology for Alzheimer’s Disease
Garrett, M. D. (2019) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2019.04.000580
Dawson, R. (2019) · Research Explorer (The University of Manchester)
Effect of Aqueous Extract of Lavandula Angustifolia on Clearance of Amyloid Beta Plaques
Kashani, M. S., Salami, M., tavirani, M. R., & kafashian (2013) · journal of ilam university of medical sciences · Cited by 2
Assessing DNA methylation epialleles for human cognitive dysfunction and brain disease
Rielly, N. J. (2020) · Nottingham ePrints (University of Nottingham)
Zukotynski, K. (2020) · TSpace (University of Toronto)
Proteolysis of the receptor for advanced glycation end products by matrix metalloproteinases
Zhang, L. (2006) · Gutenberg Open Science · doi:10.25358/openscience-4128
The role of NPxY domains in LRP1 receptor maturation and function
Pflanzner, T. (2011) · Gutenberg Open Science · doi:10.25358/openscience-3281
Diseases Mediated by the BBB: From Alzheimer's to Obesity
Banks, W. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50209-9
Cerebral amyloid angiopathy : new insights from transgenic mice
Herzig, M. C. (2004) · edoc (University of Basel) · doi:10.5451/unibas-003642738
TOR-dependent cerebrovascular aging in Alzheimer's disease.
Jahrling, J. B., & Galván, V. (2014) · PubMed
Pathogenesis of Alzheimer Disease: Metabolic Factors
(2004) · Springer eBooks · doi:10.1007/0-306-48529-x_15
(2007) · Steinkopff eBooks · doi:10.1007/978-3-7985-1787-5_7
Härd, T., & Sandberg, A. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13271974.14628100
Sultana, A., & Alauddin, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101611 · Cited by 1
Pur-alpha participates in the progression of Alzheimer's disease through direct and indirect waysPreprint
Shi, X., Ren, S., Zhang, B., Guo, S., He, W., Yuan, C., Yang, X., Ig-lzevbekhai, K., Sun, T., Wang, Q., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-21919/v1
Neuropharmacology in Alzheimer and Huntington Disease
Gupta, B., & Rohatgi, K. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815040913122010015 · Cited by 1
Ablation of cell-specific cholesterol synthesis affects cerebral β-amyloidosis
Spieth, L. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9780
“...................... 67 6.3 List of abbreviations ABC ATP binding cassette ABCA1 ATP binding cassette subfamily A member 1 ABCA7 ATP binding cassette subfamily A member 7 Aβ Amyloid β ACAT1 Acetyl-CoA Acetyltransferase 1 αCTF83 α-C-terminal fragment 83 residue AD Alzheimer´s disease ADAM10 A disintegrin and metallop…”
BackgroundInfluentialSterol Biomarker Discovery In Neurodegenerative Diseases
Pacciarini, M. (2023) · Cronfa (Swansea University) · doi:10.23889/suthesis.65375
Fathallah, S. S. (2023) · theses.fr (ABES) · doi:10.70675/cd31edacz7e53z4d37zaf55z5dfcf1f9ba3f
Mee-inta, O., Chiang, Y.-Y., Zhao, Z., Wang, T.-F., Lee, H., Huang, C., Wu, P., & Kuo, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4234881/v1
Fong, V., Kanuri, B., Traubert, O. D., Lui, M., & Patel, S. B. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02214-6
“ABCG4 is a member of the ATP-binding cassette transporter family that regulates cholesterol homeostasis; ABCG4 is predominantly expressed in the CNS (Yoshikawa et al. 2002; Cserepes et al. 2004; Bojanic et al. 2010).”
BackgroundInfluentialKanuri, S. H., & Sirrkay, P. J. (2024) · Neurology Letters · doi:10.61186/nl.3.3.19
Characterizing Protein Concentration in Cerebrospinal Fluid with T2 Component Analysis
Koizumi, T., Shimizu, S., Akiba, C., Kakizoe, H., Bandai, H., Sato, K., Nagasawa, H., Ogino, I., Nakajima, M., Yamada, S., et al. (2024) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2023-0157
Self-citationThe blood–brain barrier: Gatekeeper and obstacle in neurodegenerative disorders
Bassiony, M., Ibrahem, M. A., Youssef, D. G., Elbadry, A. M. M., & Alaboudi, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00002-6
Banks, W. A., & Erickson, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_13
Developing Arterial Drugs: Lessons from the Hepatic Artery and Other Arterial Injections
Baig, A., Gamblin, T. C., Bello, R. J., & Joshi, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-80173-0_12
Molecular determinants of extracellular TIMP-3 accumulation in Sorsby fundus dystrophyPreprint
Betts, J. H. J., Hampton, K., Strickland, D. K., Clark, S. J., Day, A. J., & Troeberg, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654781
Self-citationQi, J., He, M., Lian, T., Wang, S. H., Guo, P., Li, J., Li, J., Luo, D., Zhang, Y., Huang, Y. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251364736
“35 Consequently, the damage of BBB can be re fl ected by the alterations of above variables, including PDGFR β , GFAP, MMPs, RAGE, and LRP1.”
Hwang, S., Park, S., Lim, J.-H., & Shin, Y. G. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70196
Brain Endothelial Cell Expression in Alzheimer’s Disease Showing Stage-Associated Changes
Zheng, Z. (2025) · Advances in Alzheimer s Disease · doi:10.4236/aad.2025.143003
Morphological and functional changes of the blood–brain barrier in hypertriglyceridemia
Barabási, B. (2025) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12176
Understanding the Value of Cerebrospinal Fluid Perivascular Flow Dynamics
Zukotynski, K., & Xie, K. Y. (2025) · Radiology · doi:10.1148/radiol.252782
Shiiki, T., & Ohtsuki, S. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00424
Imaging BBB dysfunction in brain disorders
Wang, D. J. J., & Shao, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-32974-6.00001-x
Yukti, Sharma, A., Dhar, S., Ojha, R., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.004
Behera, A., Lodha, S., Sa, N., Rout, S. S., Kalyankar, G. G., Panchal, N., & Sabnani, M. K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811747125010009
Physiology and Pathophysiology of Cerebral Microcirculation
Dalkara, T. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_29-1
Furon, J., Yetim, M., Pouettre, E., de Lizarrondo, S. M., Maubert, E., Hommet, Y., Lebouvier, L., Zheng, Z., Ali, C., & Vivien, D. (2024) · Figshare · doi:10.6084/m9.figshare.26566058
Uekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24240134
Simon, M. J., Wang, M. X., Ismail, O., Braun, M., Schindler, A., Reemmer, J., Wang, Z., Haveliwala, M. A., O’Boyle, R. P., Han, W. Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19664333
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20155656
Kachlmeier, A. (2022) · Gutenberg Open Science · doi:10.25358/openscience-8128
Bernard, J. (2023) · Gutenberg Open Science · doi:10.25358/openscience-8965
Min, L.-J., Iwanami, J., Shudou, M., Bai, H.-Y., Shan, B.-S., Higaki, A., Mogi, M., & Horiuchi, M. (2020) · Figshare · doi:10.6084/m9.figshare.12097464
Li, J., Li, M., Ge, Y., Chen, J., Ma, J., Wang, C., Sun, M., Wang, L., Yao, S., & Yao, C. (2022) · Figshare · doi:10.6084/m9.figshare.19906252
Colony Stimulating Factor 1 Receptor and Blood-Brain Barrier Maintenance
Delaney, C. (2021) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Characterization of preclinical transgenic rat models for Alzheimer’s disease-like pathology
Emmerson, J. T. (2023) · eScholarship@McGill (McGill) · doi:10.82308/166
Veiculação e vetorização de fármacos ao cérebro
Polido, A. V. F. (2014) · Repositório Comum (Repositório Científico de Acesso Aberto de Portugal)
Ständer, L., Bartelt, A., & München, T. U. (2024)
Hematoentsefaalbarjääri penetreerivate peptiidide avastamine ja iseloomustamine
Nõmmik, H. K. (2025) · DSpace repository (University of Tartu)
Gallwitz, L. (2023) · MACAU: Open Access Repository of Kiel University
Gião, T. A. B. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Role of apolipoprotein E4 in alzheimer’s disease pathogenesis and emerging therapeutic strategies
Natarajan, S., & Saraswathy, S. D. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01761-0
“The results of recent research indi - cate that elevating the expression of APOER2 leads to an improvement in synaptic plasticity and lipid homeostasis in apolipoprotein E4 models (Wang et al. 2018 ; Sun et al. 2023 ; Shibata et al. 2000 ).”
Systemic Amyloid-β Metabolism in Alzheimer’s Disease
Dong-yu, F., Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_7
LeVine, S. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031485
Zhou, Z., Zhang, W., Zhai, Z., Kong, F., Zhao, Y., Xu, Y., & Sun, T. (2026) · European journal of medical research · doi:10.1186/s40001-026-04057-w
Atkinson, A. (2011) · theses.fr (ABES) · doi:10.70675/f60fc7c7za4b6z4589za6bfz951f1a27064f · Cited by 2
Boutonnet, M.-C. (2013) · theses.fr (ABES) · doi:10.70675/33d36cb4z9d85z41f4z883dz477d1ad29773
“Outre la modulation efficace du flux d’Aβ du cerveau vers le sang à travers la BHE (Shibata et al., 2000), il semble que LRP1 module la maturation, le trafic ainsi que le turnover de l’APP, ce qui peut se répercuter sur la production d’Aβ (Pietrzik et al.”
BackgroundInfluentialImplication de la phospholipase A2 cytoplamique dans la pathogénèse de la maladie d'Alzheimer
Desbène, C. (2012) · theses.fr (ABES) · doi:10.70675/9db38b81z9958z4e46z87cez29580d7f85e2
In vivo peptide biomarker screening for molecular imaging in eae neuroinflammation
Sanchez, J. V. (2013) · theses.fr (ABES) · doi:10.70675/16e10b38zf166z4d75za5a5zcce4ba71673a
Interaction du peptide beta amyloïde avec les membranes plasmiques cellulaires
Gilson, V. (2013) · theses.fr (ABES) · doi:10.70675/5a91d188zfbf8z47efza16bza77cebf6c54f
Etude des interactions des peptides beta-amyloïdes et membranes cellulaires : transport et toxicité
Bello, I. (2014) · theses.fr (ABES) · doi:10.70675/091f9c62z26b1z42e4z9139zc7bfff00735e
Hadžibegović, S. (2015) · theses.fr (ABES) · doi:10.70675/75759fbbz3be8z47edz977ezb52425d6ec69 · Cited by 1
Étude de la protéine PINK1 dans la maladie d'Alzheimer et le cancer cérébral
Goiran, T. (2016) · theses.fr (ABES) · doi:10.70675/3fcc1ed3zd075z4566z92bfz92ab5779abbe
Auboyer, L. (2018) · theses.fr (ABES) · doi:10.70675/07243ef7zb974z4ad8z97d9zd046801798b1
“· Il est estimé que 10 à 15 % des peptides Aβ peuvent rejoindre le LCR au travers du liquide interstitiel (ISF pour Intersitial Fluid), remplissant l’espace entre les cellules et les capillaires, pour ensuite rejoindre la circulation sanguine (Shibata et al., 2000).”
BackgroundDérivés puriques et physiopathologie de la maladie d’Alzheimer
Leuxe, C. (2017) · theses.fr (ABES) · doi:10.70675/0c471421zafedz4712zb5cdz02efab20d706
Ketogenic diet impacts Blood-Brain Barrier physiology : implications for Alzheimers's disease
Corsi, M. (2018) · theses.fr (ABES) · doi:10.70675/36cd4c36z2faaz4535zaafdz8f54069c5015
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






